Similar articles

• Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

  Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Group. Home PD, et al. N Engl J Med. 2007 Jul 5;357(1):28-38. doi: 10.1056/NEJMoa073394. Epub 2007 Jun 5. N Engl J Med. 2007. PMID: 17551159 Clinical Trial.
• Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan.

  Hsiao FY, Huang WF, Wen YW, Chen PF, Kuo KN, Tsai YW. Hsiao FY, et al. Drug Saf. 2009;32(8):675-90. doi: 10.2165/00002018-200932080-00006. Drug Saf. 2009. PMID: 19591532
• [Rosiglitazone: clinical data].

  Blickle JF. Blickle JF. Ann Endocrinol (Paris). 2002 Apr;63(2 Pt 2):1S27-33. Ann Endocrinol (Paris). 2002. PMID: 12037505 Review. French. No abstract available.
• Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.

  Ekström N, Svensson AM, Miftaraj M, Franzén S, Zethelius B, Eliasson B, Gudbjörnsdottir S. Ekström N, et al. Diabetes Obes Metab. 2016 Oct;18(10):990-8. doi: 10.1111/dom.12704. Epub 2016 Jul 19. Diabetes Obes Metab. 2016. PMID: 27282621
• The safety of rosiglitazone in the treatment of type 2 diabetes.

  Singh S, Loke YK. Singh S, et al. Expert Opin Drug Saf. 2008 Sep;7(5):579-85. doi: 10.1517/14740338.7.5.579. Expert Opin Drug Saf. 2008. PMID: 18759710 Review.